Cyfuse Biomedical

Cyfuse Biomedical

Tissue fabrication systems and cell-based products in japan and internationally. Learn more

Launch date
Employees
Market cap
AUD57.1m
Enterprise valuation
AUD26m (Public information from Sep 2024)
Tokyo Japan (HQ)

Financials

Estimates*

Edit
Revenues, earnings & profits over time
JPY2020202120222023
Revenues137m708m374m61.1m
% growth-415 %(47 %)(84 %)
EBITDA(289m)169m(351m)(538m)
% EBITDA margin(210 %)24 %(94 %)(881 %)
Profit(330m)143m(474m)(589m)
% profit margin(240 %)20 %(127 %)(964 %)
EV / revenue--16.1x49.0x
EV / EBITDA---17.2x-5.6x
  • Edit
DateInvestorsAmountRound
-

N/A

-
N/A

JPY1.0m

Early VC

JPY422m

Series A
N/A

JPY151m

Series A

$12.0m

Late VC
N/A

JPY1.1b

Early VC

$1.8m

Early VC
N/A

N/A

Early VC
N/A

N/A

-

$1.9m

Late VC
*
N/A

N/A

IPO
Total FundingAUD44.2m

Recent News about Cyfuse Biomedical

Edit
More about Cyfuse Biomedicalinfo icon
Edit

Cyfuse Biomedical is a pioneering company in the field of regenerative medicine, leveraging advanced 3D bioprinting technology to develop innovative medical solutions. The company operates primarily in the healthcare and biotechnology markets, focusing on creating products that aid in the regeneration of tissues and organs. Cyfuse's core clients include research institutions, hospitals, and biotech firms that are engaged in cutting-edge medical research and clinical applications.

The business model revolves around the development and commercialization of 3D bioprinters and related consumables, which are sold to medical and research facilities. Additionally, Cyfuse generates revenue through collaborative research agreements and licensing of its proprietary technology. The company's unique approach combines biology and engineering to create a platform that significantly advances the field of cellular medicine, offering new treatment options and improving patient outcomes.

Keywords: 3D bioprinting, regenerative medicine, tissue engineering, cellular therapy, biotechnology, medical research, clinical applications, healthcare innovation, bioprinters, proprietary technology.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.